Navigation Links
Pharmasset to Present at Canaccord Adams Conference
Date:8/5/2009

tment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates: RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys((R)) and Copegus((R) )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
4. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
8. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
11. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Using a bio-mimicking analog of one of ... an international research team led by Alejandro Briseno ... a major step in developing long-sought polymer architecture ... for use in electronic devices. , Briseno, ... and others at Stanford University and Dresden University ...
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
(Date:9/30/2014)... Nematicide is a type of chemical ... parasitic roundworms, found in massive quantities virtually everywhere—in ... animals. Nematicides have tended to be broad-spectrum toxicants ... through the soil. A single gram of soil ... more than 10,000 species classified, they are one ...
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... of its manufacturing process for,REOLYSIN(R) to commercial ... production and downstream processing,development was undertaken by ... located in Montreal, Canada., "Our existing ...
... Industry Expertise to Pathwork Following FDA ... Clearance and $20M Fundraising Round, SUNNYVALE, ... on oncology, announced today the,appointment of two key positions within ... Mark McDonough as Vice,President of US Sales. These professionals bring ...
... CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ), the operator ... ) is announcing a new service available,to ... business, or looking to,invest in Michigan companies ... existing resources available on the Michigan Life ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale 2Pathwork Diagnostics Announces Key Additions to Management Team 2The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
(Date:9/29/2014)... ramosum , coupled with a high-fat diet, may cause animals ... mBio , the online open-access journal of the American ... German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that ... gained weight when fed a high-fat diet. Mice that did ... when consuming a high-fat diet, and mice that had ...
(Date:9/29/2014)... 29, 2014 -- Plants have a symbiotic relationship ... pants extract nutrients and defend against invaders ... fruits and vegetables. Now, scientist have discovered that ... seeds; thus ensuring that sprouting plants are colonized ... of Notre Dame, presented their findings today at ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2Plants prepackage beneficial microbes in their seeds 2
... volume transmitted every second with every quick eye movement ... Ruhr-Universitt Bochum (RUB) and the University of Osnabrck describe ... visual cortex, the entry point for the visual information ... ". Deploying novel optical imaging methods, they demonstrated that ...
... University researchers have shown natural radioactivity within DNA can ... mutation. The research, recently published in Biochimica ... looked at natural radioactivity within human DNA on the ... bodies as well as in every living organism across ...
... explanation for how the most common strain of methicillin-resistant ... prominence. Research published in mBio , the online ... that the strain recently acquired a number of genes ... and thrive on the skin where other strains of ...
Cached Biology News:Neurons subtract images and use the differences 2Neurons subtract images and use the differences 3Radioactivity muddles the alphabet of DNA 2MRSA strain gained dominance with help from skin bacteria 2
...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: